United States: FDA Issues Draft Guidance On Determination Of Reference Product Exclusivity For Biologics

Last Updated: August 8 2014
Article by Colleen Heisey

On August 4, the U.S. Food & Drug Administration ("FDA") issued a draft guidance titled "Reference Product Exclusivity for Biological Products Filed Under Section 351(a) of the PHS Act." The draft guidance is intended to assist biological product sponsors and applicants in submitting appropriate information to FDA to enable a regulatory determination of the "first licensure" date of a reference biological product under section 351(k)(7)(C) of the Public Health Service Act ("PHS Act"), which was added to the Federal Food, Drug, and Cosmetic Act ("FD&C Act") by the Biologics Price Competition and Innovation Act of 2009.

Background

Under section 351(k) of the PHS Act, an application for a biosimilar or interchangeable biologic may not be submitted to FDA until four years after, or approved until 12 years after, first licensure of the reference biologic, respectively referred to as periods of "data exclusivity" and "market exclusivity." An additional six months of "pediatric exclusivity" may be added to the data and market exclusivities if the biologic meets the requirements for pediatric exclusivity under section 505A of the FD&C Act. In addition, seven years of orphan drug exclusivity may be applied if the biologic is indicated for a rare disease or condition under section 527(a) of the FD&C Act, in which case the biologic may not be licensed for that indication until after the expiration of the seven-year orphan drug exclusivity period or the 12-month market exclusivity period, whichever is later.

Process of Determination of "First Licensure" by FDA

Given the significance of data and market exclusivity, the determination under section 351(k) of the date of first licensure of a reference biological product submitted under section 351(a) effectively decides (i) the product's eligibility for various reference product exclusivities and (ii) the lengths of those periods of exclusivity. However, as noted by FDA in the draft guidance, "[m]aking this determination can present unique challenges given the requirements of section 351(k)(7)," which "are made more acute because of the scientific and technical complexities that may be associated with the larger and typically more complex structures of biological products ... as well as the processes by which such biological products are made."

In most cases, the date of first licensure of a reference biological product submitted under section 351(a) will be the initial date the product was licensed by FDA. However, section 351(k)(7)(C) excludes from this determination the date of licensure for the following products:

  • A supplement for the biological product that is the reference product; or
  • A subsequent application filed by the same sponsor or manufacturer of the biological product that is the reference product (or a licensor, predecessor in interest, or other related entity) for:
    • a change (not including a modification to the structure of the biological product) that results in a new indication, route of administration, dosing schedule, dosage form, delivery system, delivery device, or strength;
    • a modification to the structure of the biological product that does not result in a change in safety, purity, or potency.

As noted by FDA, "because of these exclusions, for each product licensed under section 351(a) of the PHS Act that may serve as a reference product for a biosimilar application, FDA must make a determination regarding the date of first licensure." In its draft guidance, FDA explains how it intends to make these determinations, and provides concrete examples as illustrations of its intended approach.

Identifying a Licensor, Predecessor in Interest, and "Other Related Entity." FDA explained that it "has experience in construing other provisions that require examination of the relationships between business entities." It has construed "predecessor in interest" to include an entity that has been taken over, merged with, or purchased, or has granted exclusive rights to the application or its data. An entity will be considered related if either entity owns, controls, or has the power to own or control the other entity, or the entities are under common ownership or control. FDA will also find parties related when they are or were engaged in commercial collaborations relating to the product's development.

Whether There Has Been a Structural Modification of the Product. FDA explained that in making this determination, it will consider the products' principal structural molecular features and whether they affect the same molecular target. Also, if a sponsor employs a cell line modified from that used to manufacture the previously licensed product, the sponsor would need to first demonstrate the product has been structurally modified, and then show that the modification resulted in a change in safety, purity, or potency.

If So, Whether There Has Been a Change in Safety, Purity, or Potency. FDA explained that this determination "will be made case-by-case" based on supporting evidence submitted by the sponsor. Such evidence may include preclinical or clinical studies, references to the data and information submitted in the 351(a) application of the previously licensed product, and evidence that the change will result in a meaningful benefit to public health when compared to the previously licensed biological product. Also, FDA generally will presume that a structural modification has resulted in a change to the proposed product's safety, purity, or potency if the sponsor demonstrates the product affects a different molecular target than the original product did.

Suggested Information for Submission by Section 351(a) Applicants

FDA concluded by specifying the information a sponsor should include in its 351(a) application, in correspondence related to the application, or in an amendment, depending on the timing and availability of the information during the application process. Specifically, FDA suggested the following information for submission.

  1. A list of all licensed biological products that are structurally related to the biologic being applied for, including those that share some of the principal molecular structural features, target different epitopes of the same target, and share the narrowest target that can be characterized. If a sponsor concludes that no such product has been licensed, it should provide adequate justification for its determination.
  2. For those product listed in item 1 above, a list of those for which the sponsor or any of its affiliates is or was a license holder.
  3. For those products listed in item 2 above, a description of the structural differences from the proposed product, which for protein products should include changes in amino acid sequence; differences due to post-translational events, infidelity of  translation, or transcription; differences in glycosylation patterns or tertiary structure; and differences in biological activities.
  4. For those products listed in item 2 above, evidence of the changes in safety, purity, and/or potency from the proposed product, including how the structural differences relate to these changes.

Comments Should Be Submitted by October 6

To ensure FDA considers comments before issuing the final version of the draft guidance, FDA encourages interested parties to submit comments on the draft guidance by October 6. Comments can be submitted electronically to http://www.regulations.gov [Docket No. FDA-2013-D-1165].

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Colleen Heisey
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration
Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:
  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.
  • Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.
    If you do not want us to provide your name and email address you may opt out by clicking here
    If you do not wish to receive any future announcements of products and services offered by Mondaq you may opt out by clicking here

    Terms & Conditions and Privacy Statement

    Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

    Use of www.mondaq.com

    You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

    Disclaimer

    Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

    The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

    Registration

    Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

    • To allow you to personalize the Mondaq websites you are visiting.
    • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
    • To produce demographic feedback for our information providers who provide information free for your use.

    Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

    Information Collection and Use

    We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

    We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

    Mondaq News Alerts

    In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

    Cookies

    A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

    Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

    Log Files

    We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

    Links

    This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

    Surveys & Contests

    From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

    Mail-A-Friend

    If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

    Emails

    From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

    *** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .

    Security

    This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

    Correcting/Updating Personal Information

    If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

    Notification of Changes

    If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

    How to contact Mondaq

    You can contact us with comments or queries at enquiries@mondaq.com.

    If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.

    By clicking Register you state you have read and agree to our Terms and Conditions